Document:

exv10w71

Exhibit 10.71

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

FIRST AMENDMENT TO

TRANSITION AGREEMENT DATED JANUARY 28, 2005

     This FIRST AMENDMENT to the Agreement (hereinafter defined) (this “First Amendment”),
effective this 11th day of August, 2006, is made and entered into by and between MEDICIS
PHARMACEUTICAL CORPORATION, a Delaware corporation maintaining its offices at 8125 North Hayden
Road, Scottsdale, Arizona 85258-2463 (“MEDICIS”), and aaiPharma Inc., a Delaware corporation and
the parent company of AAIPharma Inc. (formerly known as AAI International, Inc.), having offices at
2320 Scientific Park Drive, Wilmington, NC 28405 (“AAIPharma”).

RECITALS:

     A. MEDICIS and AAIPharma have executed that certain Transition Agreement, dated as of January
28, 2005 (the “Agreement”); and

     B. MEDICIS and AAIPharma desire to amend the Agreement as hereinafter provided.

     NOW, THEREFORE, in consideration of the foregoing recitals, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

     All capitalized terms not otherwise defined herein shall have the meaning as set forth in the
Agreement. The parties acknowledge and agree that this Amendment amends, and supercedes in part,
the Agreement in accordance with the terms set forth herein.

	A.	 	Attachment B to Exhibit III. Attachment B is hereby deleted in its entirety and
replaced with the revised Attachment B attached hereto.
	 
	B.	 	Attachment D to Exhibit III. Attachment D is hereby deleted in its entirety and
replaced with the revised Attachment D attached hereto.
	 
	C.	 	Binding Effect. Except as modified in this First Amendment, the Agreement shall
remain unchanged and in full force and effect. The parties represent and warrant that, as of
the Effective Date, no other agreements, written or oral, exist between the parties with
respect to the subject matter covered herein except for the Agreement and this First
Amendment. The parties acknowledge and agree that in the event of any conflict
between the terms amended pursuant to this First Amendment and the other terms of the
Agreement, the terms of this First Amendment shall govern.
	 
	D.	 	Counterparts. This First Amendment may be executed in one or more counterparts, each
of which shall be deemed an original and all of which together shall be deemed one and the
same instrument.
	 
	E.	 	Authority. Each party represents and warrants to the other party that this
Amendment is being executed by the authorized representatives of each party.

     IN WITNESS WHEREOF, the parties hereto have caused this First Amendment to be executed by
their duly authorized representatives as of the date first above written.

	 	 	 	 	 	 	 
	MEDICIS PHARMACEUTICAL CORPORATION	AAIPHARMA, INC.

	 
	By:  
	 	 	 	By:  	 	 
	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Name:
	 	 	Name:	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Title:
	 	 	Title:	 
	 
	 	 	 	 	 	 

 

 

Attachment B

Pricing

***

 

 

Attachment D

Batch Record Numbering and Expiry Dating

***

        .exv10w72

Exhibit 10.72

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

SECOND AMENDMENT TO

TRANSITION AGREEMENT DATED JANUARY 28, 2005

     This SECOND AMENDMENT to the Agreement (hereinafter defined) (this “Second Amendment”),
effective September 8, 2006 (“Effective Date”), is made and entered into by and between MEDICIS
PHARMACEUTICAL CORPORATION, a Delaware corporation maintaining its offices at 8125 North Hayden
Road, Scottsdale, Arizona 85258-2463 (“MEDICIS”), and aaiPharma Inc., a Delaware corporation and
the parent company of AAIPharma Inc. (formerly known as AAI International, Inc.), having offices at
2320 Scientific Park Drive, Wilmington, NC 28405 (“AAIPharma”).

RECITALS:

     A. MEDICIS and AAIPharma are parties to that certain Transition Agreement, dated as of January
28, 2005, as amended pursuant that certain First Amendment, dated August 11, 2006, (collectively,
the “Agreement”); and

     B. MEDICIS and AAIPharma desire to amend the Agreement as hereinafter provided.

     NOW, THEREFORE, in consideration of the foregoing recitals, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
agree as follows:

     All capitalized terms not otherwise defined herein shall have the meaning as set forth in the
Agreement. The parties acknowledge and agree that this Second Amendment amends, and supersedes in
part, the Agreement in accordance with the terms set forth herein.

	A.	 	Agreement of Quality/Technical Responsibility of Exhibit III. The Agreement of
Quality/Technical Responsibility of Exhibit III is hereby deleted in its entirety and replaced
with the revised Agreement of Quality/Technical Responsibility attached hereto.
	 
	B.	 	Binding Effect. Except as modified in this Second Amendment, the Agreement, as
previously amended, shall remain unchanged and in full force and effect. The parties
represent and warrant that, as of the Effective Date, no other agreements, written or oral,
exist between the parties with respect to the subject matter covered herein except for the
Agreement and this Second Amendment. The parties acknowledge and agree that in the event of
any conflict between the terms amended pursuant to this Second Amendment and the other terms
of the Agreement, the terms of this Second Amendment shall govern.
	 
	C.	 	Counterparts. This Second Amendment may be executed in one or more counterparts,
each of which shall be deemed an original and all of which together shall be deemed one and
the same instrument.
	 
	D.	 	Authority. Each party represents and warrants to the other party that this Second
Amendment is being executed by the authorized representatives of each party.

     IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to be executed by
their duly authorized representatives as of the Effective Date.

	 	 	 	 	 	 	 
	MEDICIS PHARMACEUTICAL CORPORATION	AAIPHARMA INC.

	 
	By:  
	 	 	 	By:  	 	 
	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Name:
	 	 	Name:	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Title:
	 	 	Title:	 
	 
	 	 	 	 	 	 

1

 

AGREEMENT OF QUALITY / TECHNICAL RESPONSIBILITY

This document constitutes the Quality/Technical Agreement (“QT Agreement”) of responsibilities for
contract pharmaceutical manufacture and/or packaging is between AAIPharma Inc., on behalf of itself
and its subsidiaries (“AAI”) and Medicis Pharmaceutical Corporation (“Medicis”). This QT Agreement
is incorporated within, and intended to supplement, the Manufacturing Terms attached as Exhibit III
to that certain Transition Agreement (the “Manufacturing Terms”) between the parties dated January
28, 2005 with respect to the Product manufactured thereunder.

This QT Agreement defines the individual responsibilities of Medicis and AAI, and in particular
defines who is responsible for the cGMP aspects of manufacturing and specifies the way in which
Product Batches will be released for sale, ensuring that the Product complies with the Regulatory
Approval and the Product Specifications.

The QT Agreement takes the form of a detailed checklist of all the activities associated with
pharmaceutical production, analysis, release, and distribution. Responsibility for each activity
is assigned either to AAI or Medicis, or is designated as not applicable (“N/A”) in the appropriate
tick box. In the event of a conflict between terms of this QT Agreement and the Manufacturing
Terms, the terms of the Manufacturing Terms shall govern.

KEY CONTACTS:

All quality issues (except medical or non-medical Product complaints, or regulatory affairs) will
be directed through the Key Quality Assurance contact, as listed below, for each party.

If any key contacts change for a party, such party will notify the other party in writing and
designate a new contact person. Other contacts within each party may be identified as needed to
facilitate communication of technical issues.

KEY CONTACTS:

	 	 	 	 	 
	Area of	 	 	 	 
	Responsibility	 	AAI	 	Medicis
	Quality Assurance

	 	***
	 	***
	 
	 	 	 	 
	Regulatory Affairs

	 	***
	 	***
	 
	 	 	 	 
	Technical Services

	 	***
	 	***
	 
	 	 	 	 
	Medical Affairs

	 	***
	 	***
	 
	 	 	 	 
	Non-medical
Product Complaints

	 	***
	 	***

 

			
	*	 	Key Quality Assurance contact
	 
	 	 	NOTE: All documents for review and approval are to be sent to quality@medicis.com

DEFINITIONS

Capitalized terms used, but not defined herein, shall have the meaning given to them in the
Manufacturing Terms.

TERMS

	 	1.	 	The term of this QT Agreement will begin on the Effective Date (see 3. below)
and will expire on the date of expiration or earlier termination of the Manufacturing
Terms.
	 
	 	2.	 	The parties will review this QT Agreement at least annually to verify that
the technical responsibilities allocated in this QT Agreement are current and valid.

2

 

	 	3.	 	The “Effective Date” of this QT Agreement will be the signature date of the
last party to sign this QT Agreement. The QT Agreement shall be fully implemented
within *** of the Effective Date.

CHANGE CONTROL PROCESS

	 	 	 	Either party may propose updates, amendments, modifications, or supplements
(collectively, the “Amendments”) to this QT Agreement. No Amendment will be valid
or effective unless made in writing and signed by duly authorized officers of both
parties.

3

 

	 	 	 	 	 	 	 	 	 
	NO.	 	RESPONSIBILITIES	 	N/A	 	Medicis	 	AAI
	1

	 	COMPLIANCE REQUIREMENTS	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	1.1

	 	Perform and maintain all audit documentation regarding supplier(s) of
Active Ingredient for the Products.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	1.2

	 	Perform and maintain all qualification documentation regarding suppliers
of Components for the Products.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	1.3

	 	Manufacture, test and package Product in strict adherence to the
approved drug application, cGMPs, and Specifications.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	1.4

	 	*** shall not subcontract any of the work to a third party without prior
written agreement of ***, which prior agreement shall not be
unreasonably withheld or delayed. *** shall be responsible for auditing
subcontractors to ensure cGMP compliance.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	1.5

	 	Provide *** with copies of all information supporting annual Product
reports for Products supplied to Medicis.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	1.6

	 	Provide *** with copies/correspondence regarding the approved drug
applications for the Products.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	1.7

	 	Notify *** and have written authorization from *** prior to implementing
any proposed changes to the facilities, manufacturing process,
materials, Specifications, and/or testing that impact the approved
registration, or that require revalidation. Identify for ***, in
writing prior to delivery, the first manufactured Batch incorporating
any approved changes.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	1.8

	 	Provide notification to the other party of any organizational and/or
personnel changes to Quality Assurance, Technical Services, or
Regulatory Affairs Contacts.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	1.9

	 	*** will make every reasonable effort to provide copies of any Form
483s, Warning Letters, Field Alerts or similar correspondence from
Governmental Authorities within one (1) business day of receipt and
subsequent response(s) relating to the Products or processes used to
produce, test, or package the Products promptly thereafter. ***
approval is required for responses related to the Products.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	1.10

	 	Notify *** within one (1) business day of any circumstances likely to
result in a recall, Product withdrawal or field correction, including
any confirmed Product failure.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	1.11

	 	Perform and maintain as current all appropriate validation, including
but not limited to: process, analytical method, cleaning, computer, and
packaging.
	 	***
	 	***
	 	***
	 
	1.12

	 	Dispose of all production residue, manufacturing rejects, tailings,
other chemicals, containers and packaging materials associated with
Products manufactured for Medicis in compliance with all applicable laws
and regulations.
	 	***
	 	***
	 	***
	 
	1.13

	 	*** will notify *** within two (2) business days, then proceed to
promptly investigate and resolve to the reasonable satisfaction of ***
all “Out-of-
	 	***
	 	***
	 	***

3

 

	 	 	 	 	 	 	 	 	 
	NO.	 	RESPONSIBILITIES	 	N/A	 	Medicis	 	AAI
	 

	 	Specification” results. *** to review and approve any
retesting scenarios in OOS investigations.	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	1.14

	 	Notify *** of any requests for information, notices of violations or
other communication from a Governmental Agency related to the Medicis
Products or processes promptly within no more than two (2) business days
after *** receipt thereof.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	1.15

	 	Notify *** of any incident affecting compliance to environmental,
occupational health and safety laws related to handling Medicis Products
or processes within three (3) business days.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2

	 	PRODUCTION AND TESTING OF BULK PRODUCT	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	2.1

	 	*** to Maintain the Master Formula (or Product structure). *** to
review and approve.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.2

	 	*** will maintain approved Specifications.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.3

	 	Provide consistent Batch identification system for bulk manufacture.
Immediately notify *** of any proposed changes to identification system
prior to implementation of any such changes.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.4

	 	Qualify Active Ingredient suppliers.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.5

	 	Maintain Active Ingredient Specification, and ensure compliance of the
Specification with regulatory and compendial requirements.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.6

	 	Procure Active Ingredient (include Certificate of Analysis, COA, for the
Active Ingredient). The Active Ingredient shall have not *** left to
expiration upon receipt at AAI. Any exceptions to the above must be
approved in writing by AAI.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.7

	 	Store Active Ingredient.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.8

	 	Sample Active Ingredient.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.9

	 	Validate and/or transfer test method for Active Ingredient to ***. ***
to approve the analytical method.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.10

	 	Analyze Active Ingredient (include documentation, COA).
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.11

	 	Release Active Ingredient.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.12

	 	Retain reference samples of Active Ingredient for a *** Product
expiration date, of the last lot using each batch of API.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.13

	 	Qualify inactive substance suppliers in accordance with ***.
Qualification does not include on-site audits.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.14

	 	Procure inactive substances (include COA).
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.15

	 	Store inactive substances.
	 	***
	 	***
	 	***

4

 

	 	 	 	 	 	 	 	 	 
	NO.	 	RESPONSIBILITIES	 	N/A	 	Medicis	 	AAI
	2.16

	 	Sample inactive substances.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.17

	 	Validate and/or transfer test methods for the inactive substances to ***.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.18

	 	Analyze inactive substances (include documentation, COA).
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.19

	 	Release inactive substances.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.20

	 	Perform Process Validation. *** to review and approve.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.21

	 	Perform Cleaning Validation. *** to review and approve.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.22

	 	Provide Bill of Materials (BOM) for bulk manufacture. *** to review and
approve.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.23

	 	Provide Manufacturing Transfer Document for transfer within ***.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.23A

	 	Review and approve the Manufacturing Transfer Document
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.24

	 	Prepare Manufacturing Instructions (Production Operating Instructions).
*** to review and approve.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.25

	 	*** will maintain Specification for bulk Product and ensure compliance
of the Specification with regulatory and compendial requirements. ***
will maintain approved Specifications.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.26

	 	Produce bulk Product (include Batch documentation).
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.27

	 	Document, investigate and resolve deviations from approved manufacturing
instructions or Specifications. *** to review and approve all
deviations. *** to be notified within two (2) business days of
discovery of a deviation.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.28

	 	Not to reprocess or salvage any partially processed or fully processed
materials without the written consent of *** unless such activities are
expressly allowed in applicable approved regulatory documents.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.29

	 	Develop bulk Product sampling plan.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.29A

	 	Review and approve the Product sampling plan.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.31

	 	Validate and/or transfer test method for bulk Product to ***. *** to
approve analytical method.
	 	***
	 	***
	 	***
	 
	2.32

	 	Analyze bulk Product.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.33

	 	Approve bulk Product for packaging.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.34

	 	Produce Certificate of Analysis for bulk Product.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.35

	 	Retain reference samples of bulk Product for the period of time
specified in AAI’s Standard Operating Procedures.
	 	***
	 	***
	 	***

5

 

	 	 	 	 	 	 	 	 	 
	NO.	 	RESPONSIBILITIES	 	N/A	 	Medicis	 	AAI
	2.36

	 	Perform manufacturing facility, equipment and instrument qualification,
preventive maintenance and calibration.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.37

	 	Perform laboratory facility, equipment and instrument qualification,
preventive maintenance and calibration.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	2.38

	 	Perform stability storage and testing of bulk Product as requested by
*** in accordance with the Manufacturing Terms or other service
estimate.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.

	 	INSPECTION, PACKAGING OF FINISHED PRODUCT	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	3.1

	 	Maintain finished Product Specification, and ensure compliance of the
Specifications with regulatory and compendial requirements.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.2

	 	Provide Batch identification system for finished Product.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.3

	 	Provide artwork and labeling text (blister, carton, leaflet, label,
etc.) to ***.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.4

	 	Perform labeling review and approval.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.5

	 	Medicis will provide Specifications for packaging materials, and ensure
compliance of the Specifications with regulatory and compendial
requirements. *** will maintain approved Specifications.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.6

	 	Validate and/or transfer test method(s) for Product packaging materials
to ***. *** to approve analytical methods.
	 	***
	 	***
	 	***
	 
	3.7

	 	Qualify packaging component and labeling suppliers in accordance with
AAI policies. Qualification does not include on-site audits.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.8

	 	Procure packaging materials.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.9

	 	Analyze packaging materials.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.10

	 	Release packaging materials.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.11

	 	Retain samples of labeling materials for a *** Product expiry date.
[NOTE: Other packaging materials need not be retained separately since
they are part of the finished Product retains].
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.12

	 	Perform Packaging Validation. *** to review and approve.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.13

	 	*** will provide Bill of Materials (BOM) for packaging. *** to review
and approve.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.14

	 	*** will prepare Packaging Instructions (Production Operating
Instructions for packaging). *** to review and approve.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.15

	 	Perform packaging operations (include documentation).
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.16

	 	Perform in-process controls during packaging (include documentation).
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.17

	 	Develop finished Product sampling plan consistent with the Manufacturing
	 	***
	 	***
	 	***

6

 

	 	 	 	 	 	 	 	 	 
	NO.	 	RESPONSIBILITIES	 	N/A	 	Medicis	 	AAI
	 	 	 	 	 	 	 	 	 
	 

	 	Terms for retain and stability samples.
Provide finished Product release sampling plan for ***
review and approval.	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	3.18

	 	Sample finished Product including retain samples, stability
samples, release samples, and customer samples.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.19

	 	Retain reference samples of finished Product for a *** past
Product expiry date.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.20

	 	Reconcile packaging materials.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.21

	 	Perform manufacturing facility, equipment and instrument
qualification, preventive maintenance and calibration.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.22

	 	Perform laboratory facility, equipment and instrument
qualification, preventive maintenance and calibration.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	3.23

	 	Document, investigate and resolve any deviations from
approved packaging instructions or Specifications. *** to
review and approve all deviations. Notify Medicis within
two (2) business days of discovery of deviations.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.

	 	TESTING AND RELEASE OF FINISHED PRODUCT	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	4.1

	 	Validate and/or transfer test method(s) for finished Product
to ***. *** to review and approve.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.2

	 	Perform laboratory equipment and instrument qualification,
preventive maintenance and calibration.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.3

	 	Analyze finished Product.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.4

	 	*** to approve shipment of finished Product to Medicis.***
to release Product for distribution.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.5

	 	Review Batch Record including all pertinent documentation
and data. Provide copy to *** for review.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.6

	 	Produce Certificate of Analysis for finished Product testing.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.7

	 	Perform stability storage and testing as requested by *** in
accordance with the Manufacturing Terms or other service
estimate. Notify Medicis immediately within one (1)
business day, if the Product fails to meet Specifications
during stability testing.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.8

	 	Stability Testing Protocol	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	Define protocol requirements.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	For each packaging configuration, place the*** production
Batches of Product on stability and *** annually.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	Pull stability samples as per the approved stability
protocol. Provide reviewed/approved test results to ***
within *** of completion of testing.

	 	***
	 	***
	 	***

7

 

	 	 	 	 	 	 	 	 	 
	NO.	 	RESPONSIBILITIES	 	N/A	 	Medicis	 	AAI
	 	 	 	 	 	 	 	 	 
	 

	 	Perform stability facility, equipment and instrument
qualification, preventive maintenance and calibration.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.9

	 	Establish approved expiration date.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.10

	 	Adverse Events and Product Complaints
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	*** shall document Product complaints and adverse event
claims. *** shall notify the other’s key contact as
specified in the Manufacturing Terms following receipt of
any Adverse Event or Product Complaint.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	*** shall promptly investigate any such complaints. ***
shall provide *** with a summary of its investigation as
soon as practicable, but in no event later than ***.
Complaints designated by *** as “high priority complaints”
shall be investigated by *** within ***.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	*** shall respond to regulatory agencies and reporters and
shall be responsible for all activities relating to medical
surveillance.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	Complete follow-up corrective action.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.11

	 	Visually examine retain reference samples of finished
Product annually. Investigate if required. Report all
results to ***.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.12

	 	Perform Annual Product Review. Provide copies of all
information supporting annual Product reporting to ***.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.13

	 	Prepare annual Product report and file with applicable
regulatory agencies.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.14

	 	Product Recall	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	Decide to initiate recall.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	Notify appropriate regulatory agencies.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	Manage recall.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	Reconcile returned Product.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.15

	 	Responsibility to Authorities	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	Liaison with Regulatory Authorities for approval,
maintenance and updating of drug application.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	Liaison with Regulatory Authorities for any site visits
related to the Products produced for Medicis. *** to notify
*** promptly within no more than one (1) business day after
being contacted regarding such site visits.

	 	***
	 	***
	 	***

8

 

	 	 	 	 	 	 	 	 	 
	NO.	 	RESPONSIBILITIES	 	N/A	 	Medicis	 	AAI
	 	 	 	 	 	 	 	 	 
	 

	 	Maintain safety/hazard and handling data on Products and Active
Ingredient.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	Maintain safety/hazard and handling data on Components.

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.16

	 	Special test requirements (specify):
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	4.17

	 	Maintain all Batch Records for a *** Product expiry date and supply
copies (true or electronic) of all such records to *** on request.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	5

	 	STORAGE AND TRANSPORTATION OF BULK PRODUCT, FINISHED PRODUCT AND
WASTE DISPOSAL	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	5.1

	 	Store bulk Product up to packaging.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	5.2

	 	Store finished Product after release by Medicis.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	5.3

	 	Store all materials under appropriate conditions of temperature,
humidity, light and cleanliness and in a manner to avoid
deterioration, theft, interference and Product contamination.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	6

	 	DOCUMENTATION	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	6.1

	 	Provide *** with complete copies of Process Validation reports for
the *** of each Product.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	6.2

	 	Provide *** with complete copies of Packaging Validation reports for
each Product.
	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	6.3

	 	Provide the following documentation to *** for each Batch:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	Executed Batch record, including copies of labeling documenting
expiration date and lot number

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	Test results for Active Ingredient and Components (upon request)

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	Manufacturing release summary: Certificate of Compliance (COC)
statement indicating Product conformance with cGMP, signed by the
responsible Quality individual performing Product approval

	 	***
	 	***
	 	***
	 
	 	 	 	 	 	 	 	 
	 

	 	If Product release testing is performed by ***, testing release
summary, Certificate of Analysis (COA), including:

	 	***
	 	***
	 	***
	 
	 

	 	- Tests performed

	 	 	 	 	 	 
	 
	 

	 	- Test methods used

	 	 	 	 	 	 
	 
	 

	 	- Test Specifications

	 	 	 	 	 	 
	 
	 

	 	- Test results including retest results if required

	 	 	 	 	 	 
	 
	 

	 	- Date of release

	 	 	 	 	 	 
	 
	 

	 	- Signature of responsible Quality individual performing testing
release

	 	 	 	 	 	 

9

 

	 	 	 	 	 
	Medicis Pharmaceutical Corporation

	 	AAIPharma Inc.	 	 
	 

	 	Quality Assurance Approval:	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	Name: Terri Magee

	 	Name:	 	 
	 

(Print/Type)

	 	 

(Print/Type)
	 	 
	Title: Director of QC

	 	Title:	 	 
	 

	 	 

	 	 
	 
	 	 	 	 
	Signature:

	 	Signature:	 	 
	 

	 	 

	 	 
	Date:

	 	Date:	 	 
	 

	 	 

	 	 
	 
	 	 	 	 
	 

	 	AAIPharma Inc.	 	 
	 

	 	Executive Approval:	 	 
	 

	 	 

	 	 
	 
	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 

(Print/Type)
	 	 
	 

	 	Title:	 	 

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00169-of-00352.parquet"}]]